Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Exley

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapyWeihua Song, Hans J J van der Vliet, Yu-Tzu Tai, et al.
Immunology|November 25, 2003
Innate immune response to encephalomyocarditis virus infection mediated by CD1dMark A Exley, Nancy J Bigley, Olivia Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerHans J van der Vliet, Hans J J van der Vliet, Henry B Koon, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2003
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashionSilke Gillessen, Yuri N Naumov, Edward E S Nieuwenhuis, et al.
Hepatology (Baltimore, Md.)|April 10, 2015
The biliary epithelium presents antigens to and activates natural killer T cellsElisabeth Schrumpf, Corey Tan, Tom H Karlsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical TrialMark A Exley, Phillip Friedlander, Nadia Alatrakchi, et al.
Nature Immunology|October 23, 2019
Control of CD1d-restricted antigen presentation and inflammation by sphingomyelinEspen Melum, Xiaojun Jiang, Kristi D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2021
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed GlioblastomaDavid W Andrews, Kevin D Judy, Charles B Scott, et al.
Nature Communications|February 6, 2024
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndromeTerese C Hammond, Marco A Purbhoo, Sapana Kadel, et al.
The Journal of Clinical Investigation|July 2, 2010
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 functionSebastian Zeissig, Stephanie K Dougan, Duarte C Barral, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapyWeihua Song, Hans J J van der Vliet, Yu-Tzu Tai, et al.
Immunology|November 25, 2003
Innate immune response to encephalomyocarditis virus infection mediated by CD1dMark A Exley, Nancy J Bigley, Olivia Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerHans J van der Vliet, Hans J J van der Vliet, Henry B Koon, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2003
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashionSilke Gillessen, Yuri N Naumov, Edward E S Nieuwenhuis, et al.
Hepatology (Baltimore, Md.)|April 10, 2015
The biliary epithelium presents antigens to and activates natural killer T cellsElisabeth Schrumpf, Corey Tan, Tom H Karlsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical TrialMark A Exley, Phillip Friedlander, Nadia Alatrakchi, et al.
Nature Immunology|October 23, 2019
Control of CD1d-restricted antigen presentation and inflammation by sphingomyelinEspen Melum, Xiaojun Jiang, Kristi D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2021
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed GlioblastomaDavid W Andrews, Kevin D Judy, Charles B Scott, et al.
Nature Communications|February 6, 2024
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndromeTerese C Hammond, Marco A Purbhoo, Sapana Kadel, et al.
The Journal of Clinical Investigation|July 2, 2010
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 functionSebastian Zeissig, Stephanie K Dougan, Duarte C Barral, et al.
Pageof 8